Phase II Investigation of Calcium Electroporation as a Treatment for Cutaneous and
Subcutaneous Malignant Tumours.
This will be a non-randomized phase II trial with the objective of evaluating the clinical
response rate of calcium electroporation treatment of malignant tumours of the skin and
assessing treatment impact on quality of life. This study will investigate the response rate
of calcium electroporation treatment of skin metastases and malignant wounds in a real-world
setting, in three different cancer centres in Northern Europe. Each centre will treat 10
patients with cancer in the skin of any histology. The patients will be treated once and
followed with regular examinations for 12 months, starting from first treatment day. All
patients will have been offered the standard of care and all available alternatives before
entering the protocol. Calcium electroporation will not be compared to other means of
The primary endpoint of this study is to evaluate the clinical overall response rate of
calcium electroporation treatment of malignant tumours of the skin after two months. A subset
of patients will undergo MR scans after treatment and another subset of patients will be
interviewed regarding treatment impact on quality of life.
Not yet recruiting
Zealand University Hospital
Results (where available)
Published on BioPortfolio: 2020-01-14T10:02:24-0500
Medical and Biotech [MESH] Definitions
Signal transduction mechanisms whereby calcium mobilization (from outside the cell or from intracellular storage pools) to the cytoplasm is triggered by external stimuli. Calcium signals are often seen to propagate as waves, oscillations, spikes, sparks, or puffs. The calcium acts as an intracellular messenger by activating calcium-responsive proteins.
Intracellular signaling peptides and proteins that bind to CALCIUM. They undergo allosteric changes when bound to CALCIUM that affects their interaction with other signal-transducing molecules. They differ from CALCIUM-SENSING RECEPTORS which sense extracellular calcium levels.
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
A class of G-protein-coupled receptors that react to varying extracellular CALCIUM levels. Calcium-sensing receptors in the PARATHYROID GLANDS play an important role in the maintenance of calcium HOMEOSTASIS by regulating the release of PARATHYROID HORMONE. They differ from INTRACELLULAR CALCIUM-SENSING PROTEINS which sense intracellular calcium levels.
A stromal interaction molecule that functions in the regulation of calcium influx following depletion of intracellular calcium in the ENDOPLASMIC RETICULUM. It translocates to the plasma membrane upon calcium depletion where it activates the CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL ORAI1.